An Open-label Extension Study to Assess the Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Adult Participants With Lupus Nephritis Who Have Completed Study Treatment in the CVAY736K12301 Core Study (SIRIUS-LN Extension)

The purpose of this 2-year extension study is the evaluation of the efficacy and safety
1. after study treatment withdrawal in patients with lupus nephritis (LN) who achieved response (complete renal response [CRR] or partial renal response [PRR]) on double-blind treatment at the end of the SIRIUS-LN core study, and
2. of open-label ianalumab 300 mg treatment in patients who, at the end of the SIRIUS-LN core study, were either already receiving ianalumab open-label treatment or did not meet CRR/PRR criteria on double-blind treatment at the end of the SIRIUS-LN core study.

Start Date16 May 2025

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

CTR20244052

/ RecruitingPhase 2

一项在弥漫皮肤型系统性硬化病参与者中评价ianalumab的疗效、安全性和耐受性的随机、双盲、平行组、安慰剂对照、多中心研究

[Translation] A randomized, double-blind, parallel-group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of ianalumab in participants with diffuse cutaneous systemic sclerosis

本研究的目的是评价ianalumab每月一次皮下给药与安慰剂相比，在弥漫皮肤型系统性硬化病参与者中的疗效、安全性和耐受性

[Translation]

The purpose of this study was to evaluate the efficacy, safety, and tolerability of ianalumab administered subcutaneously once a month compared with placebo in participants with diffuse cutaneous systemic sclerosis.

Start Date09 Jan 2025

Sponsor / Collaborator

China Novartis Institutes for BioMedical Research Co., Ltd.

[+2]

NCT06411639

/ WithdrawnPhase 1

A Multicenter, Open-label, Single-arm, Multiple-dose Study to Characterize the Pharmacokinetics, Safety and Tolerability of Subcutaneous Ianalumab in Chinese Adult Participants With Autoimmune Diseases

The purpose of this pharmacokinetic (PK) study is to describe the PK profile of ianalumab following s.c. administration in Chinese participants with systemic lupus erythematosus (SLE) and/or Sjögren's disease (SjD). Collection of intensive PK data from Chinese population had been designed in the ianalumab Phase 3 studies of SjD CVAY736A2302 (NCT05349214) and lupus nephritis (LN) CVAY736K12301 (NCT05126277) on an optional basis. This study is conducted to provide supplementary Chinese PK data in addition to the intensive PK data from the two Phase 3 studies .

Start Date25 Nov 2024

Sponsor / Collaborator

Novartis Pharmaceuticals Canada, Inc.

100 Clinical Results associated with Ianalumab

100 Translational Medicine associated with Ianalumab

100 Patents (Medical) associated with Ianalumab

Literatures (Medical) associated with Ianalumab

01 Sep 2024·Expert Review of Hematology

Novel treatments for immune thrombocytopenia: targeting platelet autoantibodies

Review

Author: Arnold, Donald M. ; Harnett, Brian ; Al‐Samkari, Hanny ; Dalmia, Shreyash ; Al-Samkari, Hanny ; Arnold, Donald

INTRODUCTION:

Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by low platelets and an increased risk of bleeding. Platelet autoantibodies target major platelet glycoproteins and cause Fc-mediated platelet destruction in the spleen and reticuloendothelial systems. As mechanisms of disease, platelet autoantibodies are important therapeutic targets. Neonatal Fc receptor (FcRn) antagonists are a new class of therapeutics that reduce the half-life of immunoglobulin G including pathogenic platelet autoantibodies. Spleen tyrosine kinase (Syk) inhibitors interfere with Fc-mediated platelet clearance. Bruton's tyrosine kinase (BTK) inhibitors and B-cell activating factor (BAFF) inhibitors reduce antibody production. The efficacy of these targeted therapies provides new support for the role of platelet autoantibodies in pathogenesis of ITP even these antibodies can be difficult to detect.

AREAS COVERED:

This review includes an in-depth exploration of the pathophysiologic mechanisms of ITP, focusing on autoantibodies. Treatments outlined in this review include a) FcRn antagonists, b) complement inhibitors, c) B-cell directed therapies such as BTK inhibitors, and anti-BAFF agents, d) Syk inhibitors, e) plasma-cell directed therapies, and f) novel cellular therapeutic products.

EXPERT OPINION:

Platelet autoantibodies are often elusive in ITP, yet novel treatments targeting this pathway reinforce their role in the pathogenesis of this autoimmune platelet disorder.

01 Jun 2024·DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT

Review

Author: Witte, Torsten ; Ernst, Diana ; Zehrfeld, Nadine

01 Apr 2024·International immunopharmacology

The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review

Review

Author: Najar Nobari, Minou ; Lotfi, Zahra ; Heidari, Nazila ; Ghane, Yekta ; Jaffary, Fariba ; Heidari, Amirhossein ; Nilforoushzadeh, Mohammad Ali ; Najar Nobari, Niloufar

Immune thrombocytopenia (ITP) is an autoimmune-driven disease characterized by increased destruction and impaired platelet production resulting in an enhanced risk of bleeding. Immunosuppressant agents are the most common treatment strategies for ITP. Despite their efficacy, these medications often cause unpredictable side effects. Recent investigations revealed that patients with ITP exhibit elevated B-cell activating factor (BAFF) levels in both their spleens and serum. Belimumab, a BAFF inhibitor, illustrated a promising therapeutic avenue for managing ITP by interfering with BAFF activity and long-lived plasma cell production. Both clinical and experimental studies have yielded positive outcomes when combining rituximab with an anti-BAFF monoclonal antibody in treating ITP. In addition, ianalumab, a monoclonal antibody with a dual mechanism that targets BAFF-R and deletes peripheral BAFF-R⁺ B cells, is currently being used for ITP treatment [NCT05885555]. The upcoming results from novel BAFF inhibitors, such as ianalumab, could offer clinicians an additional therapeutic option for treating ITP.

News (Medical) associated with Ianalumab

19 Mar 2025

·www.prnewswire.com

CABLIVI Market Reports Positive Growth - Strong Momentum Expected to Continue | DelveInsight

Developed by Sanofi, CABLIVI is the first FDA-approved nanobody therapy for this condition. Increasing awareness, improved diagnostic rates, and rising demand for targeted therapies in hematology drive the market growth. With its niche indication and high treatment costs, CABLIVI holds a strong position in the rare disease therapeutics segment. LAS VEGAS, March 19, 2025 /PRNewswire/ -- DelveInsight's " CABLIVI Market Size, Forecast, and Market Insight Report" highlights the details around CABLIVI, a von Willebrand factor (vWF)-directed antibody fragment. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of CABLIVI. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Ablynx NV's CABLIVI (caplacizumab-yhdp) Overview CABLIVI is an antibody fragment that targets von Willebrand factor (vWF) and is used to treat adult patients with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange and immunosuppressive therapy. It works by binding to the A1-domain of vWF, preventing its interaction with platelets, which helps reduce vWF-mediated platelet adhesion and consumption. CABLIVI is approved in both the US and EU for treating aTTP. In 2024, CABLIVI sales reached €249 million, reflecting a 9.7% increase, driven by a rise in the number of patients identified for suitable treatment in the US, as well as new launches in Europe and other regions. The recommended CABLIVI dosing schedule is as follows: Day 1: Administer an 11 mg intravenous bolus injection at least 15 minutes before plasma exchange, followed by an 11 mg subcutaneous injection after the exchange on the same day. During Plasma Exchange Therapy: Administer 11 mg subcutaneously once daily after each plasma exchange session. After Plasma Exchange Therapy: Continue with 11 mg subcutaneous injections once daily for 30 days after the final plasma exchange. If signs of persistent underlying disease, such as low ADAMTS13 activity, are still present, treatment can be extended for up to 28 additional days. CABLIVI treatment should be discontinued if the patient experiences more than two recurrences of aTTP while on the medication. Learn more about CABLIVI projected market size for thrombocytopenia @ CABLIVI Market Potential Thrombocytopenia is a medical condition where the platelet count in the blood drops below the normal level (<150,000/µL). Common causes include heparin-induced thrombocytopenia, chemotherapy-induced thrombocytopenia, thrombocytopenia linked to chronic liver disease, immune thrombocytopenia (ITP), and thrombotic thrombocytopenic purpura (TTP). Among the 7MM, the United States reported the highest number of thrombocytopenia cases, accounting for about 40% of the total cases in 2023, according to DelveInsight. Treatment for thrombocytopenia varies based on its cause and severity, with the primary goal of preventing bleeding-related complications and improving patient outcomes. Approved therapies for thrombocytopenia in the US include MULPLETA, DOPTELET, TAVALISSE, PROMACTA, NPLATE, CABLIVI, GAMMAPLEX, OCTAGAM, RHOPHYLAC, and PRIVIGEN. Additionally, danaparoid, argatroban, and lepirudin are approved for treating thrombosis in patients with heparin-induced thrombocytopenia. For severe thrombocytopenia related to chronic liver disease, treatment options include platelet transfusion, splenic artery embolization, splenectomy, and transjugular intrahepatic portosystemic stent shunt (TIPSS) placement. The US holds approximately 60% of the thrombocytopenia market share, surpassing the combined market size of the EU4, the UK, and Japan. Market growth is expected to be driven by an increasing patient population, the introduction of new therapies, and deeper market penetration within the 7MM. Discover more about the thrombocytopenia market in detail @ Thrombocytopenia Market Report Emerging Competitors of CABLIVI The potential therapies that can mark a significant change in the thrombocytopenia treatment landscape and give tough competition to CABLIVI include Rilzabrutinib (Sanofi), Ianalumab (Novartis), Mezagitamab (Takeda), PF-06835375 (Pfizer), Povetacicept (Vertex), Cevidoplenib (Genosco/Oscotec), and Efgartigimod (ARGX-113) (Argenx), among others. In December 2024, Sanofi shared encouraging Phase III results at ASH for rilzabrutinib, its investigational oral BTK inhibitor, in patients with ITP. In June 2024, Takeda reported late-breaking Phase IIb data on Mezagitamab, highlighting its potential to revolutionize the treatment of Primary ITP. In Novartis' Q2 2024 update, the company forecasted key trial results: VAYHIT1 (NCT05653349) for first-line therapy, expected in 2026, and VAYHIT2 (NCT05653219) for second-line therapy, anticipated in 2025. Novartis also aims to file for ianalumabin approval in both first- and second-line ITP treatment by 2027 or later. To know more about the number of competing drugs in development, visit @ CABLIVI Market Positioning Compared to Other Drugs Key Milestones of CABLIVI In June 2022, at the 27th Annual European HematologyAssociation (EHA) Congress, Sanofi presented long-term safety and efficacy results from the post-HERCULES trial (NCT02878603), a three-year prospective follow-up study of patients with acquired thrombotic thrombocytopenic purpura (aTTP) who completed the Phase 3 HERCULES trial. In February 2019, the FDA approved CABLIVI (caplacizumab-yhdp) injection as the first therapy specifically indicated for treating adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening blood clotting disorder. It is to be used in combination with plasma exchange and immunosuppressive therapy. In September 2018, the European Commission approved CABLIVI (caplacizumab) for marketing, authorizing its use in treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder. CABLIVI is the first therapy specifically designed for aTTP treatment. In July 2017, Ablynx announced a research collaboration and global exclusive licensing agreement with Sanofi, aiming to develop and commercialize Nanobody-based therapies for treating various immune-mediated inflammatory diseases. Discover how CABLIVI is shaping the thrombocytopenia treatment landscape @ CABLIVI FDA Approval CABLIVI Market Dynamics The primary driver of CABLIVI's market growth is the increasing recognition and diagnosis of aTTP, coupled with improved access to specialized treatments. Growing awareness among healthcare providers and advancements in diagnostic capabilities have facilitated early and accurate diagnosis, thereby boosting the demand for targeted therapies like CABLIVI. The drug's ability to prevent microthrombi formation, shorten the duration of plasma exchange, and reduce the risk of relapses has positioned it as a preferred option in the treatment landscape for aTTP. Moreover, Sanofi's robust commercial infrastructure and strategic marketing efforts have further contributed to market penetration and adoption. Despite its therapeutic benefits, CABLIVI faces challenges related to its high cost and reimbursement complexities. The specialized nature of aTTP treatment, combined with the requirement for hospital-based administration and close monitoring, adds to the overall cost burden on healthcare systems and patients. Additionally, competition from alternative therapies, including plasma exchange and immunosuppressive treatments, may limit its market expansion. Regulatory hurdles and the need for long-term safety data could also impact the drug's market trajectory. The CABLIVI market is expected to grow steadily, driven by ongoing clinical research and potential label expansions into related thrombotic disorders. Increased investments in rare disease treatments and orphan drug incentives are likely to support market growth. Moreover, the rise in strategic collaborations and partnerships to improve patient access and streamline reimbursement processes could enhance market uptake. However, balancing pricing pressures with broader patient access will remain a key factor in sustaining long-term market performance. Dive deeper to get more insight into CABLIVI's strengths & weaknesses relative to competitors @ CABLIVI Market Drug Report Table of Contents Related Reports Acquired Thrombotic Thrombocytopenic Purpura Pipeline Acquired Thrombotic Thrombocytopenic Purpura Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acquired thrombotic thrombocytopenic purpura companies, including Sanofi, TargED Biopharmaceuticals, Takeda, Genentech, Alexion Pharmaceuticals, among others. Thrombocytopenia Market Thrombocytopenia Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key thrombocytopenia companies including Sanofi, Principia Biopharma, Baxalta, Takeda, Argenx, Millennium Pharmaceuticals, Biotest, GC Pharma, Genosco (Subsidiary of Oscotec), Rigel Pharmaceuticals, Kissei Pharmaceutical, Shionogi & Co., Ltd, Amgen, Novartis, Zenyaku Kogyo, among others. Thrombocytopenia Pipeline Thrombocytopenia Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key thrombocytopenia companies, including Takeda, Argenx, Keros Therapeutics, Principia Biopharma, Momenta Pharmaceuticals, Veralox Therapeutics, Novartis Pharmaceuticals, Pfizer, HUTCHMED, Principia Biopharma, Genosco, UCB, among others. Immune Thrombocytopenia Market Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key immune thrombocytopenia companies including Rigel Pharmaceuticals, Kissei Pharmaceutical, Sobi (Dova Pharmaceuticals), Amgen, Argenx, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultLicense out/inPhase 3Drug Approval

31 Jan 2025

·www.fiercebiotech.com

Novartis gives up on anti-CD40 antibody to treat Sjögren\'s due to \'benefit/risk profile\'

Novartis had already given up developing iscalimab for liver transplant patients in 2022.\n Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s syndrome.On a fourth-quarter earnings call with the media this morning, Novartis’ chief medical officer and head of development Shreeram Aradhye, M.D., told Fierce Biotech that the Swiss pharma had stopped work on iscalimab “based on our assessment that the benefit/risk [profile] for what we have seen was not compatible with a competitive profile.”Iscalimab had previously shown promise in treating Sjögren’s, an immune disorder that causes dry eyes and a dry mouth. Phase 2 results showed “initial clinical benefit over placebo in two distinct populations of patients,” according to a write-up in The Lancet journal last year.Novartis had already given up developing iscalimab for liver transplant patients in 2022 after a phase 2 trial found the drug had a “less favorable risk-benefit profile” than tacrolimus, which Astellas Pharma sells as Prograf. At the time, Novartis had still been eyeing up a potential approval for iscalimab in Sjögren’s in 2026 if the data had gone its way. Despite now dropping iscalimab entirely, Aradhye said Sjögren’s “remains an area of interest for us, because it is an underserved disease with a lot of patients who need alternative options.”“Ianalumab, which is our dual mechanism, B cell depleting antibody, is actually the one that will read out in this year on our trial in Sjögren’s,” he said in response to a question from Fierce. “It is the one trial where in phase 2 we have shown meaningful differences in patients with this very difficult to treat disease.”Last year, Sanofi crossed off Sjögren’s from the list of targeted indications for its CD40L monoclonal antibody frexalimab after seeing phase 2 efficacy data.Novartis removed one other drug from its pipeline this morning in the form of LNA043. The ANGPTL3 agonist had been in development for osteoarthritis, but Novartis said the program had been discontinued following a phase 2 readout.

$Novartis gives up on anti-CD40 antibody to treat Sjögren\'s due to \'benefit/risk profile\'$

Phase 2Clinical ResultADCClinical Trial Failure

31 Jan 2025

·endpts.com

Novartis claims best earnings in years, validating shift to pure-play strategy

Novartis said Friday that last year was one of its “strongest” financial performances in its history following a multiyear reorg as a pure-play pharma company, bolstered by steady growth of its top three medicines and a skyrocketing cholesterol franchise. CEO Vas Narasimhan said on a media call that the company exceeded its full-year guidance for both sales and operating income. The Swiss drugmaker’s 2024 sales grew 12% to $45.4 billion, according to an earnings release . The update was not a complete surprise, because the company upped its sales guidance through 2028 in November. Novartis’ cholesterol drug Leqvio saw the most growth in 2024, with sales soaring 112% to $754 million. But its top three best sellers were heart failure medicine Entresto ($7.8 billion), psoriasis treatment Cosentyx ($6.1 billion) and multiple sclerosis drug Kesimpta ($3.2 billion). In 2023, the company completed a long-term restructuring process that saw it integrate its pharmaceuticals and oncology business units into a so-called innovative medicines unit, and zero in on four core therapeutic areas: cardiovascular, renal and metabolic (CRM), as well as oncology, immunology and neuroscience. “When you look at [this change] from a value creation standpoint, in January 2018 the market capitalization of Novartis was $196 billion, and you can see today that [it] stands at over $200 billion,” Narasimhan said on the second media call. “The strategy of focusing the company has unlocked value and actually enabled Novartis to be much stronger for the long run.” Last year, the drugmaker slashed the size of its development and commercial functions with an eye to a leaner structure that would allow it to focus on “the biggest opportunities” in its pipeline. It’s targeting 15 new launches or label expansions over the next few years, starting with a potential indication for its immunoglobulin A nephropathy drug Fabhalta. The factor B inhibitor was due for an FDA adcomm meeting next month to discuss its risk-benefit profile in C3 glomerulopathy, but the agency called the meeting off earlier this week. “Our understanding is that the FDA no longer deemed it necessary to hold an advisory committee meeting,” Narasimhan told reporters. “We think it’s based on the overall data package we’ve been able to generate and the additional follow-on data that we’ve provided.” Narasimhan also stressed that Novartis remains a leader in the radiopharmaceutical space, with close to $2 billion in yearly sales from radioligand products, a global manufacturing footprint and more than 15 assets in the clinic using lutetium or actinium isotopes. The company made several investments in the approach last year, including a $1 billion bet on Mariana Oncology. Novartis plans to carry on with this kind of dealmaking , Narasimhan said. “But I think it’s really important to note that right now, lutetium is the isotope that has the most data and is the only approved isotope,” he continued, adding that newer isotopes such as actinium and lead have yet to demonstrate the necessary risk-benefit profile for approval and broad use. Also on the call, the company’s chief medical officer Shreeram Aradhye said it had discontinued development of a Phase 2 candidate for Sjögren’s syndrome. Novartis dropped work on anti-CD40 antibody iscalimab because its risk-benefit profile to date was not competitive, Aradhye said. But the company is still advancing another antibody program for Sjögren’s called ianalumab. In 2022, the drugmaker gave up on advancing iscalimab for liver transplant patients for similar reasons. Editor’s note: This story has been updated to add more comments from the company’s calls.

Phase 2

100 Deals associated with Ianalumab

External Link

KEGG	Wiki	ATC	Drug Bank
-	Ianalumab	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Systemic Lupus Erythematosus	Phase 3	Japan	China Novartis Institutes for BioMedical Research Co., Ltd.	02 Mar 2023
Systemic Lupus Erythematosus	Phase 3	Japan	Novartis Pharma AG	02 Mar 2023
Systemic Lupus Erythematosus	Phase 3	Japan	Novartis Pharma Stein AG	02 Mar 2023
Systemic Lupus Erythematosus	Phase 3	Japan	Novartis Pharmaceuticals Corp.	02 Mar 2023
Systemic Lupus Erythematosus	Phase 3	Brazil	Novartis Pharma Stein AG	02 Mar 2023
Systemic Lupus Erythematosus	Phase 3	Brazil	China Novartis Institutes for BioMedical Research Co., Ltd.	02 Mar 2023
Systemic Lupus Erythematosus	Phase 3	Bulgaria	Novartis Pharmaceuticals Corp.	02 Mar 2023
Systemic Lupus Erythematosus	Phase 3	Canada	China Novartis Institutes for BioMedical Research Co., Ltd.	02 Mar 2023
Systemic Lupus Erythematosus	Phase 3	Canada	Novartis Pharma Stein AG	02 Mar 2023
Systemic Lupus Erythematosus	Phase 3	Canada	Novartis Pharma AG	02 Mar 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05885555 (ASH2024)	Phase 2	Purpura, Thrombocytopenic, Idiopathic	-	Ianalumab 9 mg/kg	fpqhikfjxf(orpkppupyg) = all 10 patients (100%) and 3 patients (30%) experienced any-grade adverse events (AEs) and Grade ≥3 AEs, respectively. Six patients had infections and 2 patients had infusion-related reactions; all of these events were Grade 1 or 2. No patients discontinued treatment due to AEs. After Week 25 there was one death due to pulmonary edema, which was assessed as unrelated to ianalumab. No safety signal was detected up to data cutoff. siejvmytsp (asnxcpllii ) View more	-	09 Dec 2024
NCT03656562 (CVAY736X2208, EULAR 12024 \| EULAR 22024) Manual	Phase 2	Systemic Lupus Erythematosus	67	ianalumab 300 mg subcutaneous	tzpfcindpt(tonjndovyz) = idbjrsuhfh nnaptmbbou (twzfiwincu )	Positive	14 Jun 2024
				placebo	tzpfcindpt(tonjndovyz) = ughcovmjby nnaptmbbou (twzfiwincu )
EULAR2023	Not Applicable	Systemic Lupus Erythematosus	67	Ianalumab	udwzopqvqz(xrarvtiufg) = 2 AE-related dropouts occurring during open-label treatment, one in ianalumab arm (morphoea) and one with placebo (worsening of SLE) upbzpyhdgo (wlfejvvzwy ) View more	-	31 May 2023
				Placebo
NCT03400176 (AACR2023) Manual	Phase 1	Chronic Lymphocytic Leukemia	39	VAY736+ibrutinib	mahmvvtotv(ubfzemcyuv) = vzbngxfmbi wfuudffqai (gomatxbuly ) View more	Positive	15 Apr 2023
				VAY736+ibrutinib (1L)	mahmvvtotv(ubfzemcyuv) = fkwgrcpntj wfuudffqai (gomatxbuly ) View more
NCT03287414 (CTgov)	Phase 2	Idiopathic Pulmonary Fibrosis	30	Standard of Care (SoC)+VAY736 (VAY736)	hnotzxnwup(wtbqfezalv) = hjtvznwkys tqferftkmw (oycpbrjwef, 0.1116) View more	-	10 Mar 2023
				Placebo (Placebo)	hnotzxnwup(wtbqfezalv) = qaretqcikh tqferftkmw (oycpbrjwef, 0.0773) View more
NCT03400176 (ASH 12021 \| ASH 22021) Manual	Phase 1	Chronic Lymphocytic Leukemia First line \| Second line	32	Ibrutinib+Ianalumab	qzcncpdiys(ipylkhuoqm) = pnlvaqbsna xfvtdzjfkw (uisztujdck ) View more	Positive	05 Nov 2021
NCT01930175 (CTgov)	Phase 2	Pemphigus	13	VAY736 (VAY736 3 mg/kg)	gcfzxzyzsh(gfkpgiqfhn) = wnbafdrrpb nbkicgwvzp (nskadmplku, 1.836) View more	-	19 Oct 2020
				VAY736 (VAY736 10 mg/kg)	gcfzxzyzsh(gfkpgiqfhn) = awmnqmyamd nbkicgwvzp (nskadmplku, 8.273) View more
EULAR2020	Phase 2	Primary Sjögren's syndrome anti-Ro/SSA+	190	VAY736 300mg	liryfwiayd(rhjgomwbck) = wtrducfusq fgwijdzxmh (osadpqrbmr )	Positive	03 Jun 2020
				Placebo	liryfwiayd(rhjgomwbck) = irtdsasovj fgwijdzxmh (osadpqrbmr )
NCT02038049 (CTgov)	Phase 2	Multiple Sclerosis, Relapsing-Remitting	8	VAY736 (VAY736)	uxdhrndchu = xcjholgglj flehygfnoh (fcswuggtja, rkwtgowxeu - jvxvuxurzb) View more	-	30 Oct 2019
				Placebo (Placebo to VAY736)	uxdhrndchu = lfbthqudyc flehygfnoh (fcswuggtja, qrpeljvkhn - dffqsktjei) View more
NCT02149420 (CVAY736X2201, Pubmed) Manual	Phase 2	Primary Sjögren's syndrome	27	ianalumab	ccbgmstynj(adkluyrbbx) = A similar trend showing positive therapeutic effect by ianalumab was observed across the primary clinical outcome (ESSDAI) and all secondary clinical outcomes (ESSPRI, Multidimensional Fatigue Inventory, Short Form-36, global assessments by physician and patient) versus the placebo-treated group. dewbnrrtmr (tnmkmtfily ) View more	Positive	01 May 2019
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis